Date: 2012-03-06
Type of information: Grant
Company: Lanthio Pharma (The Netherlands)
Investors: European Eurostars Programme (EU)
Amount: €180,000
Funding type: grant
Planned used: The funding will be used to finance a 2.5 year collaboration with the Institute of Pharmaceutical Biology, University of Bonn.
Others: Lanthio Pharma, a Dutch peptide drug discovery company, has been awarded a Eurostars grant of €180,000. The project proposal of Lanthio Pharma is a 2.5 year collaboration with the Institute of Pharmaceutical Biology, University of Bonn. The project concerns the activity and specificity testing of Lanthio Pharma\'s lanthionine-stabilized therapeutic peptides in human cells via Dynamic Mass Redistribution (DMR) by Prof. Kostenis in Bonn.DMR uses a specific light beam which is sent through cultured human cells. When a peptide binds to a receptor, a signal is transmitted which leads to migration of light-responsive molecules. This molecular redistribution reflects which receptor pathway is activated. This can be used to study which receptor(s) a lanthionine-peptide activates and how effectively. This is important since the lanthionine-stabilization may modulate the receptor specificity and may yield either variants with reduced or unwanted activity or optimal variants with enhanced activity and enhanced specificity. Taken together this collaboration will yield early value to Lanthio Pharma\'s lanthionine- peptide drug discovery projects.
Therapeutic area: Technology - Services
